Filing Flows › Sanara MedTech (SMTI) › Q4 2024
Sanara MedTech (SMTI) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 25, 2025
Sanara MedTech (SMTI) reported revenue of $26.3M for the fourth quarter 2024 (Q4 2024), +49% from a year earlier and +21% from the quarter before. Operating margin was -1.4%, net loss $1.7M (6.5% of revenue).
Sanara MedTech, Q4 2024: revenue $26.3M (+49% year over year), operating margin -1.4%, net loss $1.7M, operating cash flow $932K. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $26.3M | +21% | +49% |
| Operating profit | −$375K | — | — |
| Net earnings | −$1.7M | — | — |
| Operating cash flow | $932K | -55% | — |
| Free cash flow | $860K | -58% | — |
What changed
Revenue was $26.3M in Q4 2024, up 49% year over year and up 21% from the previous quarter. Soft Tissue Repair Products was the largest line at 89% of revenue.
Gross margin was 91.4%, up 1.6 points from a year earlier. Operating costs exceeded revenue by $375K, an operating margin of -1.4%. Operating expenses grew 51% against revenue growth of 49%. The quarter ended with a net loss of $1.7M, narrower than the previous quarter's $2.9M loss. Minority interests bore $162K of it: to shareholders the quarter was a loss of $1.5M. Net interest and other expense of $1.3M was the main reason.
Operating cash flow was $932K. Non-cash charges added back $1.6M of depreciation and amortization and $1.2M of share-based compensation. Working capital and other items used $171K. Capital expenditures of $72K left free cash flow of $860K.
Questions
What was Sanara MedTech's revenue in the fourth quarter 2024?
Sanara MedTech (SMTI) reported revenue of $26.3M for the fourth quarter 2024 (Q4 2024), +49% from a year earlier and +21% from the quarter before.
Was Sanara MedTech profitable in the fourth quarter 2024?
Operating loss was $375K (-1.4% of revenue) and net loss $1.7M.
Source: Sanara MedTech 10-K on SEC EDGAR.